Form 4: Tango Therapeutics Director Mace Rothenberg Acquires Shares in Open Market

Director Mace Rothenberg of Tango Therapeutics has acquired 20,000 shares of common stock through open market purchases.

Summary

• Mace Rothenberg, a director at Tango Therapeutics, purchased 10,000 shares of common stock on November 14, 2024, at a price of $3.62 per share.
• He then purchased an additional 10,000 shares on November 18, 2024, at a price of $3.78 per share.
• Following these transactions, Mr. Rothenberg directly owns 31,250 shares of Tango Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's open market purchases, which suggests confidence in the company. However, it's not a major event, hence the moderate score.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The open market purchases suggest a genuine belief in the company's value.

Industry Context

Insider trading activity is closely monitored by investors as it can provide insights into management's view of the company's prospects. These purchases by a director are generally seen as a positive sign.

Comparison to Industry Standards

• Insider purchases are common across the biotech industry, and this activity is not unusual.
• The size of the purchase is relatively small compared to some insider transactions in larger biotech companies, but it is still a meaningful purchase for an individual director.

Stakeholder Impact

• The purchases may positively influence investor confidence in Tango Therapeutics.
• The increased share ownership by a director could be seen as a positive signal to the market.

Key Dates

Keywords

Tango Therapeutics, TNGX, insider trading, Mace Rothenberg, stock purchase, director, SEC Form 4